PW 1-7 Ventricular Assist Devices As Bridge To Transplant Or
Transcrição
PW 1-7 Ventricular Assist Devices As Bridge To Transplant Or
PW 1-7 Ventricular Assist Devices As Bridge To Transplant Or Recovery in Pediatrics And Adolescents With Terminal Heart Failure Zimpfer D.(1), Riebandt J.(1), Schlögelhofer T.(2), Haberl T.(1), Mahr S.(1), Mlczoch E.(3), Voitl J.(3), Michel-Behnke I.(3), Schima H.(2), Laufer G.(1) Klinische Abteilung f. Herzchirurgie, Medizinische Universität Wien (1); Center for Medical Physics and Biomedical Engineering, Medizinische Universität Wiem (2); Abteilung für Pädiatrische Kardiologie Univ. Klinik für Kinder und Jugendheilkunde, Medizinische Universität Wien (3) Background: Ventricular assist devices (VAD) are increasingly beeing used as bridge to transplant or recovery in pediatrics and adoleoscents with terminal heart failure. We present our institutional experience at the pediatric heart center Vienna with three different VAD systems. Methods: A VAD was implanted in 10 pediatric patients (mean age 7.0±6.3, range 0-17yrs, mean weight 35.1±44.2, range 5.4-150kg, male 30%) in severe heart failure refractory to therapy from April 2010 to June 2013 at the pediatric heart center Vienna. Caues of heart failure were dilative cardiomyopathy (40%), restrictive cardiomyopathy (20%), myocarditis (20%) and failure of univentricular palliations (20%). Depending on patients size and underlying disease a Berlin Heart Excor BIVAD (30%), LVAD (20%), RVAD (10%), a Heartware LVAD (20%) or Thoratec Heartmate II LVAD (10%) were used. Results: VAD implantation was feasible in all patients. Of the 10 patients included in the present analysis 40% were successfully bridged to cardiac transplantation, 20% were weaned from the assist device and 40% are currently on the assist device awaiting cardiac transplantation. Mortality during VAD support was 0%. One patient experienced an CT proven stroke during VAD support. Mean duration of VAD support was 70±68 days. Conclusion: Ventricular Assist Devices are an efficient and a safe treatment option for pediatric and adolescent patients as bridge to cardiac transplantation or recovery.